

Resolution n°13-2025-e

Scaling the Optimal Use of Multiple ACTs to Prevent Antimalarial Drug Resistance (STOP AMDR)

Recalling Unitaid Executive Board Resolution n°6-2024-e of 8 January 2024, in which the Board provided its go-ahead for the development by the Unitaid Secretariat of a full grant agreement package for the proposed project 'Scaling the Optimal Use of Multiple ACTs to Prevent Antimalarial Drug Resistance- STOP AMDR' (the "Project"); and Acknowledging the recommendations of the Secretariat and the Proposal Review Committee, the Executive Board authorizes the Executive Director to commit up to USD 26,536,625 for the Project (including up to USD 170,000 earmarked for activities relating to Climate & Health and up to USD 4,400,000 earmarked for ACT procurement and market shaping activities), subject to availability of funds.

Funding is conditional upon signature of a legal agreement between Unitaid and Jhpiego Corporation.

Lead Organization: Jhpiego Corporation

Project Duration: 4 years

Marisol Touraine
Chair of the Executive Board

Date: 2 June 2025

hanisel Tunes w